Prescient Therapeutics

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Prescient Therapeutics (ASX:PTX) are focused on developing novel, personalised therapies for a range of cancers.

Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches which seek to improve patient outcomes, whilst also new tools for clinicians in combating cancer.

Prescient has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Prescient has licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.

Prescient Therapeutics is working to rapidly expand the application of universal CAR-T therapies, capable of addressing all cancers, including solid tumours. We believe it’s about targets and tools.

OmniCAR, a universal CAR-T platform employing technology licensed from UPenn, the pioneer and world leader in CAR-T, as well as Oxford University, will allow unprecedented control and flexibility over current generation CAR-T app
Ticker:
PTX
Exchange:
ASK
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
OmniCAR
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Three
Speaker
photo
Vice President Business Development and Alliances
Prescient Therapeutics Limited